1-3 of 3
Melanie Hayes, PhD
Close
Sort by
Journal Articles

Molecular and Genetic Characterization of Fit, Elderly Patients Receiving Oral Fludarabine, Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As Initial Treatment of Chronic Lymphocytic Leukemia (CLL)

Xavier C Badoux, MB BS, Giles Best, BSc (Hons), PhD, Sara Gabrielli, Miss, Melanie Hayes, PhD, Ying Zhu, PhD, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Bryone J Kuss, MBBS, PhD FRCPA, FRACP
Journal: Blood
Blood (2014) 124 (21): 1959.
https://doi.org/10.1182/blood.V124.21.1959.1959
Published: 2014
Journal Articles

Genomic Profiling In Fit, Elderly Patients Receiving Oral Fludarabine, Oral Cyclophosphamide and Intravenous Rituximab (ALLG CLL5 OFOCIR trial) As Initial Treatment Of Chronic Lymphocytic Leukemia (CLL)

XAVIER BADOUX, MBBS FRACP FRCPA, Giles Best, BSc (Hons) Ph.D., Sara Gabrielli, Miss, Ying Zhu, PhD, Melanie Hayes, PhD, Bryone J Kuss, MBBS, PhD, FRCPA, William Stevenson, MBBS, PhD, Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA
Journal: Blood
Blood (2013) 122 (21): 1624.
https://doi.org/10.1182/blood.V122.21.1624.1624
Published: 2013
Journal Articles

Panobinostat, An Oral Pan-Histone Deacetylase (HDAC) Inhibitor Activates a Microrna Signature That Targets Rad51 To Attenuate Homologous DNA Repair and Sensitize AML Cells To Sapacitabine

Deepa Sampath, PhD, Alma Zecevic, PhD, Brett Ewald, PhD, Melanie Hayes, PhD, Chaomei Liu, BSc, Guido Marcucci, MD, William Plunkett, PhD
Journal: Blood
Blood (2013) 122 (21): 822.
https://doi.org/10.1182/blood.V122.21.822.822
Published: 2013